Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
802 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-03-10
Study Completion Date
2022-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study compares two blood pressure targets and two oxygenation targets in the post-resuscitation care of comatose out-of-hospital cardiac arrets patients. Using a novel method the blood pressure-intervention is double-blinded. The oxygenation-intervention is open-label. As a subordinate study, the patients will be randomized 1:1 to active fever-control with an automated feedback temperature control-device for 36 or 72 hours following return of spontaneous circulation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Pressure and Cerebral Blood Flow After Cardiac Arrest
NCT05434910
Out-Of-Hospital Cardiac Arrest
Post-Cardiac Arrest Syndrome
UNKNOWN
NA
Bedside Monitoring of Cerebral Energy State During the Peri-cardiac Arrest Period
NCT03095742
Cardiac Arrest
Neurological Complication
Post-Cardiorespiratory Arrest Coma
COMPLETED
NA
Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation
NCT02698917
Out-of-Hospital Cardiac Arrest
COMPLETED
NA
rEduction of oXygen After Cardiac arresT: a Pilot Study
NCT02499042
Heart Arrest
COMPLETED
PHASE2
Diagnostic Value of Arterial Blood Gas Analysis in Prehospital Patients
NCT03006692
Unconscious (Psychology)
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In comatose patients resuscitated from out of hospital cardiac arrest (OHCA), neurological injuries remain the leading cause of death. The in-hospital mortality is reported at 30-50%, and the total mortality, although improved substantially over the last decade, remain to be significant, in most countries at up to 90%. An adequate blood pressure must be maintained in the post-cardiac arrest patient i order to optimize neurological recovery and avoid further brain injury. Blood pressure targets in post-resuscitation guidelines are based on limited clinical evidence. Furthermore registry and clinical data suggest a u-shaped relationship of outcome with levels of oxygen supplementation. Blinded, randomized, clinical trials addressing specific blood pressure- or oxygenation-targets during the post-resuscitation care, have not been performed.
The current trial addresses strategies for neuroprotection using a 2-by-2 design of two different target blood pressure levels and two different oxygenation levels.
Intervention:
* 'Low-normal MAP' (appoximately 63 mmHg) vs. 'high-normal MAP' (approximately 77 mmHg) (double blind intervention) and
* Low-normal oxygenation (9-10 kPa) vs. high-normal oxygenation (13-14) kPa (open label).
* As a subordinate study, the patients will be randomized 1:1 to active fever-control with an automated feedback temperature control device for 72 hours or to 36 hours following return of spontaneous circulation.
Design: National collaborative, randomized clinical trial randomizing 800 comatose out-of-hospital cardiac arrest patients undergoing targeted temperature management (TTM) to the specified interventions.
The investigators have planned the following sub-studies:
Sub-study 1: Devopment and validation af a method for double blinded allocation to different blood pressure targets.
Hypothesis: It is possible to develop a method for double blinded allocation of patients to different blood pressure targets in clinical trials.
Sub-study 2: Assessment of different blood pressure targets and relation to renal function during TTM.
Hypothesis: Different blood presure goals will affect biomarkes of renal function after cardiac arrest.
Sub-study 3: To investigate the hemodynamic profil in relation to different blood pressure targets after cardiac arrest.
Hypothesis: Blood pressure and vassopressor-doses are related to hemodynamic parameters, such as systemic vaskular resistence index and cardiac index.
Sub-study 4: To investigate the hemodynamic profil in relation to different oxygenation targets after cardiac arrest.
Hypothesis: Lower oxygenation targets are related to higher pulmonary vascular resistance.
Sub-study 5: The prognostic value of automated videobased assessment of pupillary dilatation and reaction to light. Derivation and validation of relevant cut-off for introducing pupillomtry as part of the prognostication
INTERIM ANALYSIS There will be an independent DSMC arranging an independent statistician to conduct primarily a blinded interim analysis at time points of their choosing. The DSMC will be able to request unblinding of data coordinated by the data managing agency. An interim analysis is planned after inclusion of 200 and 400 patients.
For the BP intervention, a blinded interim analysis of vasorepressor need and recorded blood pressures is planned after 50 patients, to monitor blinding of treatment allocation and that a clinically relevant blood pressure separation between groups is achieved. Vasopressor needs in terms of vasopressor need in a variance component model is expected to differ. New sites will be monitored for these factors after inclusion of 50 patients.
EARLY STOPPING CRITERIA After an interim analysis the DSMC may suggest to the steering committee that the trial should be stopped early. No specific criteria to guide the DSMB will be put forward.
ACCOUNTABILITY PROCEDURE FOR MISSING DATA/POPULATION FOR ANALYSIS Trial sites will be asked to complete all CRFs and other forms if missing data is found in the electronic database. Missing data will be reported in the publications. More than 5% missing data will result in multiple imputation with the creation of 5-10 imputed datasets to be analysed separately and the aggregated into one estimate of intervention effect on the primary and secondary outcomes. Analyses will be performed according to the modified intention to treat principle with patients lost to follow up included in the denominator.
SUBGROUP ANALYSIS AND DESIGN VARIABLES Subgroups will be analysed according to pre-defined design variables: over or under median age, shockable rhythm, gender, the presence of shock at admission, diagnosed AMI and time from arrest to ROSC. Difference in intervention effect estimates according to subgroup will be declared exclusively based on a statistically significant test of interaction.
DIRECT ACCESS TO SOURCE DATA/DOCUMENTATION The principal investigator and the site investigators will permit monitoring, audits, review of ethical committees and regulatory authorities direct access to source data and documentation, blinded to treatment allocation.
DATA HANDLING AND RECORD KEEPING Individual patient data will be handled as ordinary chart records and will be kept according to the legislation (e.g. data protection agencies) of the countries of each health system. The study database will be stored for 15 years and anonymised if requested by the relevant authorities.
Danish legislation regarding the respect for patients physical and mental integrity and rights will be respected, Approval for storing data relevant to the trial, including potentially sensitive information has been approved by the relevant authorities.
QUALITY CONTROL AND QUALITY ASSURANCE A monitoring plan will be published before start of the trial. The monitoring will include: inclusion and absence of exclusion criteria, consent obtained in all patients.
All trial sites will be provided with sufficient information to participate in the trial. The site investigator will be responsible for that all relevant data is entered into the electronic CRFs. The CRFs will be constructed in order to assure data quality with predefined values and ranges on all data entries.
STATISTICAL METHODS The combined primary outcome will be reported as proportional hazard of experiencing one of two endpoints (death or poor neurological status at hospital discharge), differences tested with a log rank test. Other proportions are expected to be normally distributed; therefore a t-test is applied. Survival analyses are performed using proportional hazard models, survival is adjusted for site.
Furthermore pre-specified analysis of interaction for design variables: sex, age (median), time to ROSC (median), shockable rhythm, STEMI, pre-existing hypertension, pre-existing chronic obstructive pulmonary disease.
SIGNIFICANCE A two-sided significance level of 0.05 will be applied to all endpoints. No adjustment for the factorial design is made, as no interaction is expected.
SAMPLE SIZE ESTIMATION Sample size estimation is based on blinded BP target allocation and on the assumption that no interaction of the two interventions exist.
The combined primary outcome is time to death or hospital discharge in a state of CPC 3 or 4. The investigators are planning a study with 400 subjects in each group, an accrual interval of 48 months, and additional follow-up after the accrual interval of 3 months. Prior data indicate the 6 months mortality is 33% overall. Assuming a mortality of 28% in the superior group compared to 38% in the inferior groups the investigators will need to include 732 patients in total or 846 patients in total to achieve a power of 0.8 and 0.9 respectively. The Type I error probability associated with this test of the null hypothesis that the experimental and control survival curves are equal is 0.05.
Loss of final measurement is expected but from the experience from previous trial the number of missing follow-up assessments is small (\<5%) and will not result in an increase of the number of patients needed.
The current trial addresses strategies for neuroprotection using a 2-by-2 design of two different target blood pressure levels and two different oxygenation levels.
Intervention:
* 'Low-normal MAP' (appoximately 63 mmHg) vs. 'high-normal MAP' (approximately 77 mmHg) (double blind intervention) and
* Low-normal oxygenation (9-10 kPa) vs. high-normal oxygenation (13-14) kPa (open label).
* As a subordinate study, the patients will be randomized 1:1 to active fever-control with an automated feedback temperature control device for 72 hours or to 36 hours following return of spontaneous circulation.
Design: National collaborative, randomized clinical trial randomizing 800 comatose out-of-hospital cardiac arrest patients undergoing targeted temperature management (TTM) to the specified interventions.
The investigators have planned the following sub-studies:
Sub-study 1: Devopment and validation af a method for double blinded allocation to different blood pressure targets.
Hypothesis: It is possible to develop a method for double blinded allocation of patients to different blood pressure targets in clinical trials.
Sub-study 2: Assessment of different blood pressure targets and relation to renal function during TTM.
Hypothesis: Different blood presure goals will affect biomarkes of renal function after cardiac arrest.
Sub-study 3: To investigate the hemodynamic profil in relation to different blood pressure targets after cardiac arrest.
Hypothesis: Blood pressure and vassopressor-doses are related to hemodynamic parameters, such as systemic vaskular resistence index and cardiac index.
Sub-study 4: To investigate the hemodynamic profil in relation to different oxygenation targets after cardiac arrest.
Hypothesis: Lower oxygenation targets are related to higher pulmonary vascular resistance.
Sub-study 5: The prognostic value of automated videobased assessment of pupillary dilatation and reaction to light. Derivation and validation of relevant cut-off for introducing pupillomtry as part of the prognostication
INTERIM ANALYSIS There will be an independent DSMC arranging an independent statistician to conduct primarily a blinded interim analysis at time points of their choosing. The DSMC will be able to request unblinding of data coordinated by the data managing agency. An interim analysis is planned after inclusion of 200 and 400 patients.
For the BP intervention, a blinded interim analysis of vasorepressor need and recorded blood pressures is planned after 50 patients, to monitor blinding of treatment allocation and that a clinically relevant blood pressure separation between groups is achieved. Vasopressor needs in terms of vasopressor need in a variance component model is expected to differ. New sites will be monitored for these factors after inclusion of 50 patients.
EARLY STOPPING CRITERIA After an interim analysis the DSMC may suggest to the steering committee that the trial should be stopped early. No specific criteria to guide the DSMB will be put forward.
ACCOUNTABILITY PROCEDURE FOR MISSING DATA/POPULATION FOR ANALYSIS Trial sites will be asked to complete all CRFs and other forms if missing data is found in the electronic database. Missing data will be reported in the publications. More than 5% missing data will result in multiple imputation with the creation of 5-10 imputed datasets to be analysed separately and the aggregated into one estimate of intervention effect on the primary and secondary outcomes. Analyses will be performed according to the modified intention to treat principle with patients lost to follow up included in the denominator.
SUBGROUP ANALYSIS AND DESIGN VARIABLES Subgroups will be analysed according to pre-defined design variables: over or under median age, shockable rhythm, gender, the presence of shock at admission, diagnosed AMI and time from arrest to ROSC. Difference in intervention effect estimates according to subgroup will be declared exclusively based on a statistically significant test of interaction.
DIRECT ACCESS TO SOURCE DATA/DOCUMENTATION The principal investigator and the site investigators will permit monitoring, audits, review of ethical committees and regulatory authorities direct access to source data and documentation, blinded to treatment allocation.
DATA HANDLING AND RECORD KEEPING Individual patient data will be handled as ordinary chart records and will be kept according to the legislation (e.g. data protection agencies) of the countries of each health system. The study database will be stored for 15 years and anonymised if requested by the relevant authorities.
Danish legislation regarding the respect for patients physical and mental integrity and rights will be respected, Approval for storing data relevant to the trial, including potentially sensitive information has been approved by the relevant authorities.
QUALITY CONTROL AND QUALITY ASSURANCE A monitoring plan will be published before start of the trial. The monitoring will include: inclusion and absence of exclusion criteria, consent obtained in all patients.
All trial sites will be provided with sufficient information to participate in the trial. The site investigator will be responsible for that all relevant data is entered into the electronic CRFs. The CRFs will be constructed in order to assure data quality with predefined values and ranges on all data entries.
STATISTICAL METHODS The combined primary outcome will be reported as proportional hazard of experiencing one of two endpoints (death or poor neurological status at hospital discharge), differences tested with a log rank test. Other proportions are expected to be normally distributed; therefore a t-test is applied. Survival analyses are performed using proportional hazard models, survival is adjusted for site.
Furthermore pre-specified analysis of interaction for design variables: sex, age (median), time to ROSC (median), shockable rhythm, STEMI, pre-existing hypertension, pre-existing chronic obstructive pulmonary disease.
SIGNIFICANCE A two-sided significance level of 0.05 will be applied to all endpoints. No adjustment for the factorial design is made, as no interaction is expected.
SAMPLE SIZE ESTIMATION Sample size estimation is based on blinded BP target allocation and on the assumption that no interaction of the two interventions exist.
The combined primary outcome is time to death or hospital discharge in a state of CPC 3 or 4. The investigators are planning a study with 400 subjects in each group, an accrual interval of 48 months, and additional follow-up after the accrual interval of 3 months. Prior data indicate the 6 months mortality is 33% overall. Assuming a mortality of 28% in the superior group compared to 38% in the inferior groups the investigators will need to include 732 patients in total or 846 patients in total to achieve a power of 0.8 and 0.9 respectively. The Type I error probability associated with this test of the null hypothesis that the experimental and control survival curves are equal is 0.05.
Loss of final measurement is expected but from the experience from previous trial the number of missing follow-up assessments is small (\<5%) and will not result in an increase of the number of patients needed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Out-of-Hospital Cardiac Arrest
Blood Pressure
Hemodynamic Instability
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
FACTORIAL
Multicenter, randomized trial in 2\*2 factorial design allocating comatose OHCA patients to one of two target blood pressures (double blind) and restrictive vs. liberal oxygenation (open label) during ICU stay with blinded outcome evaluation.
Sample size: 800 patients. Patient will be allocated 1:1; for all interventions, no interaction with regards to outcome is expected.
Sample size: 800 patients. Patient will be allocated 1:1; for all interventions, no interaction with regards to outcome is expected.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Target blood pressure will be blinded by offsetting the blood pressure measurering module.
The oxygenation- and fever control interventions will be open label. Further life-sustaining treatment will be delivered according to standard procedures and withdrawal of active intensive care will be at the discretion of the treating physicians, but must be delayed for at least 108 hours post ROSC. The steering group and the management group will be blinded to the type of intervention during the entire trial period, when handling the trial database.
Follow-up at 30 days (phone call) and 90 days (meeting) will be performed by personnel unaware of the allocation group, treatment complications at the ICU, if they occurred or specialized neurological rehabilitation.
The oxygenation- and fever control interventions will be open label. Further life-sustaining treatment will be delivered according to standard procedures and withdrawal of active intensive care will be at the discretion of the treating physicians, but must be delayed for at least 108 hours post ROSC. The steering group and the management group will be blinded to the type of intervention during the entire trial period, when handling the trial database.
Follow-up at 30 days (phone call) and 90 days (meeting) will be performed by personnel unaware of the allocation group, treatment complications at the ICU, if they occurred or specialized neurological rehabilitation.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low normal MAP and low normal PaO2
MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
Group Type
ACTIVE_COMPARATOR
Low normal MAP
Intervention Type
OTHER
The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
Low normal PaO2.
Intervention Type
OTHER
The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
High normal MAP and low normal PaO2
MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
Group Type
ACTIVE_COMPARATOR
High normal MAP
Intervention Type
OTHER
The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Low normal PaO2.
Intervention Type
OTHER
The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
Low normal MAP and high normal PaO2
MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
Group Type
ACTIVE_COMPARATOR
Low normal MAP
Intervention Type
OTHER
The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
High normal PaO2
Intervention Type
OTHER
The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
High normal MAP and high normal PaO2
MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
Group Type
ACTIVE_COMPARATOR
High normal MAP
Intervention Type
OTHER
The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Low normal PaO2.
Intervention Type
OTHER
The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low normal MAP
The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
Intervention Type
OTHER
High normal MAP
The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
Intervention Type
OTHER
Low normal PaO2.
The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
Intervention Type
OTHER
High normal PaO2
The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Mean arterial blood pressure at 63 mmHg.
Mean arterial blood pressure at 77 mmHg .
PaO2 at 9-10 kPa.
PaO2 at 13-14 kPa.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥18 years
2. OHCA of presumed cardiac cause
3. Sustained ROSC
4. Unconsciousness (GCS \<8) (patients not able to obey verbal commands) after sustained ROSC
2. OHCA of presumed cardiac cause
3. Sustained ROSC
4. Unconsciousness (GCS \<8) (patients not able to obey verbal commands) after sustained ROSC
Exclusion Criteria
1. Conscious patients (obeying verbal commands)
2. Females of childbearing potential (unless a negative HCG test can rule out pregnancy within the inclusion window)
3. In-hospital cardiac arrest (IHCA)
4. OHCA of presumed non-cardiac cause, e.g. after trauma or dissection/rupture of major artery OR Cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation, hanging).
5. Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient).
6. Suspected or confirmed acute intracranial bleeding
7. Suspected or confirmed acute stroke
8. Unwitnessed asystole
9. Known limitations in therapy and Do Not Resuscitate-order
10. Known disease making 180 days survival unlikely
11. Known pre-arrest CPC 3 or 4
12. \>4 hours (240 minutes) from ROSC to screening
13. Systolic blood pressure \<80 mm Hg in spite of fluid loading/vasopressor and/or inotropic medication/intra-aortic balloon pump/axial flow device
14. Temperature on admission \<30°C.
2. Females of childbearing potential (unless a negative HCG test can rule out pregnancy within the inclusion window)
3. In-hospital cardiac arrest (IHCA)
4. OHCA of presumed non-cardiac cause, e.g. after trauma or dissection/rupture of major artery OR Cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation, hanging).
5. Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient).
6. Suspected or confirmed acute intracranial bleeding
7. Suspected or confirmed acute stroke
8. Unwitnessed asystole
9. Known limitations in therapy and Do Not Resuscitate-order
10. Known disease making 180 days survival unlikely
11. Known pre-arrest CPC 3 or 4
12. \>4 hours (240 minutes) from ROSC to screening
13. Systolic blood pressure \<80 mm Hg in spite of fluid loading/vasopressor and/or inotropic medication/intra-aortic balloon pump/axial flow device
14. Temperature on admission \<30°C.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Sponsor Role
collaborator
Jesper Kjaergaard
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jesper Kjaergaard
MD, Ph.d., DMSc.
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jesper Kjaergaard, Md, DMSc
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Copenhagen University Hospital, Rigshospitalet
Copenhagen, København Ø, Denmark
Site Status
Depart med Cardiothoracic Intensive Care, Odense University Hospital
Odense, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Meyer MAS, Beske RP, Molstrom S, Grand J, Obling LER, Wiberg S, Borregaard B, Schneekloth S, Kaad SG, Christensen PM, Christoffersen C, Frikke-Schmidt R, Schmidt H, Moller JE, Kjaergaard J, Hassager C. Neurofilament light chain for prognostication after cardiac arrest-first steps towards validation. Crit Care. 2025 Aug 6;29(1):348. doi: 10.1186/s13054-025-05579-1.
Reference Type
DERIVED
Linde L, Beske RP, Meyer MAS, Molstrom S, Grand J, Helgestad OKL, Ravn HB, Schmidt H, Kjaergaard J, Hassager C, Moller JE. Hemodynamic Characteristics and Prognostic Implication of Modified Society for Cardiovascular Angiography and Interventions Shock Classification in Comatose Patients With Out-of-Hospital Cardiac Arrest. J Am Heart Assoc. 2025 Jan 7;14(1):e036659. doi: 10.1161/JAHA.124.036659. Epub 2024 Dec 20.
Reference Type
DERIVED
Grand J, Granholm A, Wiberg S, Schmidt H, Moller JE, Molstrom S, Meyer MAS, Josiassen J, Beske RP, Dahl JS, Obling LER, Frydland M, Borregaard B, Lind Jorgensen V, Hartvig Thomsen J, Aalbaek Madsen S, Nyholm B, Hassager C, Kjaergaard J. Lower vs. higher blood pressure targets during intensive care of comatose patients resuscitated from out-of-hospital cardiac arrest-a Bayesian analysis of the BOX trial. Eur Heart J Acute Cardiovasc Care. 2025 Jan 31;14(1):14-23. doi: 10.1093/ehjacc/zuae142.
Reference Type
DERIVED
Nyholm B, Grand J, Obling LER, Hassager C, Moller JE, Schmidt H, Othman MH, Kondziella D, Horn J, Kjaergaard J. Validating quantitative pupillometry thresholds for neuroprognostication after out-of-hospital cardiac arrest. A predefined substudy of the Blood Pressure and Oxygenations Targets After Cardiac Arrest (BOX)-trial. Intensive Care Med. 2024 Sep;50(9):1484-1495. doi: 10.1007/s00134-024-07574-6. Epub 2024 Aug 20.
Reference Type
DERIVED
Grand J, Hassager C, Schmidt H, Molstrom S, Nyholm B, Obling LER, Meyer MAS, Illum E, Josiassen J, Beske RP, Hoigaard Frederiksen H, Dahl JS, Moller JE, Kjaergaard J. Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial. Circ Heart Fail. 2024 Jun;17(6):e011437. doi: 10.1161/CIRCHEARTFAILURE.123.011437. Epub 2024 Jun 7.
Reference Type
DERIVED
Jeppesen KK, Rasmussen SB, Kjaergaard J, Schmidt H, Molstrom S, Beske RP, Grand J, Ravn HB, Winther-Jensen M, Meyer MAS, Hassager C, Moller JE. Acute kidney injury after out-of-hospital cardiac arrest. Crit Care. 2024 May 18;28(1):169. doi: 10.1186/s13054-024-04936-w.
Reference Type
DERIVED
Meyer MAS, Hassager C, Molstrom S, Borregaard B, Grand J, Nyholm B, Obling LER, Beske RP, Meyer ASP, Bekker-Jensen D, Winther-Jensen M, Jorgensen VL, Schmidt H, Moller JE, Kjaergaard J. Combined effects of targeted blood pressure, oxygenation, and duration of device-based fever prevention after out-of-hospital cardiac arrest on 1-year survival: post hoc analysis of a randomized controlled trial. Crit Care. 2024 Jan 12;28(1):20. doi: 10.1186/s13054-023-04794-y.
Reference Type
DERIVED
Grand J, Hassager C, Schmidt H, Molstrom S, Nyholm B, Hoigaard HF, Dahl JS, Meyer M, Beske RP, Obling L, Kjaergaard J, Moller JE. Serial assessments of cardiac output and mixed venous oxygen saturation in comatose patients after out-of-hospital cardiac arrest. Crit Care. 2023 Oct 27;27(1):410. doi: 10.1186/s13054-023-04704-2.
Reference Type
DERIVED
Rasmussen SB, Jeppesen KK, Kjaergaard J, Hassager C, Schmidt H, Molstrom S, Beske RP, Grand J, Ravn HB, Winther-Jensen M, Meyer MAS, Moller JE. Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest. Circulation. 2023 Dec 5;148(23):1860-1869. doi: 10.1161/CIRCULATIONAHA.123.066012. Epub 2023 Oct 4.
Reference Type
DERIVED
Nyholm B, Grand J, Obling LER, Hassager C, Moller JE, Schmidt H, Othman MH, Kondziella D, Kjaergaard J. Quantitative pupillometry for neuroprognostication in comatose post-cardiac arrest patients: A protocol for a predefined sub-study of the Blood pressure and Oxygenations Targets after Out-of-Hospital Cardiac Arrest (BOX)-trial. Resusc Plus. 2023 Sep 26;16:100475. doi: 10.1016/j.resplu.2023.100475. eCollection 2023 Dec.
Reference Type
DERIVED
Hassager C, Schmidt H, Moller JE, Grand J, Molstrom S, Beske RP, Boesgaard S, Borregaard B, Bekker-Jensen D, Dahl JS, Frydland MS, Hofsten DE, Isse YA, Josiassen J, Lind Jorgensen VR, Kondziella D, Lindholm MG, Moser E, Nyholm BC, Obling LER, Sarkisian L, Sondergaard FT, Thomsen JH, Thune JJ, Veno S, Wiberg SC, Winther-Jensen M, Meyer MAS, Kjaergaard J. Duration of Device-Based Fever Prevention after Cardiac Arrest. N Engl J Med. 2023 Mar 9;388(10):888-897. doi: 10.1056/NEJMoa2212528. Epub 2022 Nov 6.
Reference Type
DERIVED
Schmidt H, Kjaergaard J, Hassager C, Molstrom S, Grand J, Borregaard B, Roelsgaard Obling LE, Veno S, Sarkisian L, Mamaev D, Jensen LO, Nyholm B, Hofsten DE, Josiassen J, Thomsen JH, Thune JJ, Lindholm MG, Stengaard Meyer MA, Winther-Jensen M, Sorensen M, Frydland M, Beske RP, Frikke-Schmidt R, Wiberg S, Boesgaard S, Lind Jorgensen V, Moller JE. Oxygen Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022 Oct 20;387(16):1467-1476. doi: 10.1056/NEJMoa2208686. Epub 2022 Aug 27.
Reference Type
DERIVED
Kjaergaard J, Moller JE, Schmidt H, Grand J, Molstrom S, Borregaard B, Veno S, Sarkisian L, Mamaev D, Jensen LO, Nyholm B, Hofsten DE, Josiassen J, Thomsen JH, Thune JJ, Obling LER, Lindholm MG, Frydland M, Meyer MAS, Winther-Jensen M, Beske RP, Frikke-Schmidt R, Wiberg S, Boesgaard S, Madsen SA, Jorgensen VL, Hassager C. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022 Oct 20;387(16):1456-1466. doi: 10.1056/NEJMoa2208687. Epub 2022 Aug 27.
Reference Type
DERIVED
Kjaergaard J, Schmidt H, Moller JE, Hassager C. The "Blood pressure and oxygenation targets in post resuscitation care, a randomized clinical trial": design and statistical analysis plan. Trials. 2022 Feb 24;23(1):177. doi: 10.1186/s13063-022-06101-6.
Reference Type
DERIVED
Grand J, Hassager C, Schmidt H, Moller JE, Molstrom S, Nyholm B, Kjaergaard J. Hemodynamic evaluation by serial right heart catheterizations after cardiac arrest; protocol of a sub-study from the Blood Pressure and Oxygenation Targets after Out-of-Hospital Cardiac Arrest-trial (BOX). Resusc Plus. 2021 Dec 10;8:100188. doi: 10.1016/j.resplu.2021.100188. eCollection 2021 Dec.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-16033436
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Automated Chest Compression in Cardiac Arrest
NCT00641069
COMPLETED
PEEP vs. ZEEP in Out-of-Hospital-Cardiac-Arrest
NCT06836830
RECRUITING
NA
OHCA Sports in Denmark
NCT05045729
UNKNOWN
Automatic Ventilation in Prehospital Resuscitation on OHCA
NCT06067204
RECRUITING
NA
Ventilation Monitoring in OHCA
NCT04988906
COMPLETED
NA
The Ventilation During In-hospital Cardiac Arrest Study
NCT06809309
RECRUITING
Monitoring of Cardiac Function With 3-axis Accelerometers
NCT01926067
COMPLETED
Detecting a Volume Deficit During Spontaneous Breathing
NCT02549482
COMPLETED
NA
Hypoxemia in the First 24 Hours After Trauma - an Observational Study
NCT06256692
COMPLETED
Hyperoxia Before and After Cardiac Arrest and Myocardial Damage
NCT03571074
COMPLETED
Supplemental Oxygen in Hypovolemia
NCT05150418
COMPLETED
PHASE1
Early WAKE-up Predictors After Out-of-Hospital Cardiac Arrest
NCT06979700
RECRUITING
CPR Quality and Use of Feedback for OHCA
NCT04152252
COMPLETED
Brain Oxygenation During Cardiopulmonary Resuscitation
NCT03464123
COMPLETED
Quality of Cardiopulmonary Resuscitation Pre- and Intra Hospital
NCT04295291
NOT_YET_RECRUITING
Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea
NCT00708526
COMPLETED
NA
Definition of Hemodynamic Thresholds in Out-of-Hospital Cardiac Arrest
NCT03172468
WITHDRAWN
Feasibility of End-tidal Oxygen Concentration Monitoring During Preoxygenation for Intubation in the Intensive Care Unit.
NCT05409573
RECRUITING
NA
Dispatcher-Assisted CPR: Low-Dose, High-Frequency Simulation-Based Training
NCT04085692
COMPLETED
NA
Continuous Chest Compressions vs AHA Standard CPR of 30:2
NCT01372748
COMPLETED
PHASE4
Monitoring of Intubation and Ventilation During Resuscitation
NCT00204217
COMPLETED
PHASE2
Sex-unique Disparities in Survival and Resuscitation After Out-of-hospital Cardiac Arrest - a Danish Analysis
NCT05583084
COMPLETED
Ventilation in Cardiac Arrest
NCT04657393
TERMINATED
NA
Transitions Between Clinical Circulatory States After Out-of-hospital Cardiac Arrest
NCT02648061
COMPLETED
Out-of-hospital Cardiac Arrest (OHCA) Biomarkers
NCT03112486
COMPLETED